Compare Amphastar Pharmaceuticals Inc (AMPH) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Southern Copper Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Southern Copper Corp trades at $194 (market cap $166.96B). The key difference: Southern Copper Corp is far larger — about 193.3× Amphastar Pharmaceuticals Inc's market cap, and Southern Copper Corp pays a 2.23% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | SCCO | |
|---|---|---|
Market Cap | $863.95M | $166.96B |
Sector | Health | Basic Materials |
52-Week High | $30.81 | $218.85 |
52-Week Low | $16.87 | $93.70 |
Enterprise Value | $1.26B | $168.25B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Southern Copper (SCCO) trades at $199.06, up 3.12% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $2.01 vs. $1.98, revenue growth from $13.42B in 2025 to projected $15.8B in 2026, and exceptional profitability with 35.87% net margin. Recent corporate actions include dividends and stock splits, while institutional activity shows increased positions from Dimensional Fund Advisors and CalPERS.
SCCO presents growth potential driven by strong earnings performance and AI-driven copper demand, but faces risks from analyst skepticism (41.38% sell ratings) and valuation concerns with P/E of 29.51. The stock trades above consensus price target of $153.64, suggesting limited near-term upside despite positive technical momentum and fundamental strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
